Australia markets closed

Karyopharm Therapeutics Inc. (KPTI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
14.94-0.38 (-2.48%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close15.32
Open15.27
Bid14.98 x 800
Ask15.00 x 1000
Day's range14.86 - 15.35
52-week range13.39 - 29.61
Volume2,338,458
Avg. volume2,092,777
Market cap1.1B
Beta (5Y monthly)0.92
PE ratio (TTM)N/A
EPS (TTM)-2.89
Earnings date11 Feb 2021 - 15 Feb 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est32.00
  • Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
    PR Newswire

    Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update

    Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2020 total revenue estimates including net product sales for XPOVIO, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, and provided additional updates on XPOVIO's commercial progress.

  • Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    PR Newswire

    Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 50,500 shares of Karyopharm's common stock to 12 newly-hired employees, with a grant date of December 31, 2020. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Karyopharm to Present at 39th Annual J.P. Morgan Healthcare Conference
    PR Newswire

    Karyopharm to Present at 39th Annual J.P. Morgan Healthcare Conference

    Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Monday, January 11 at 4:30 p.m. ET, followed by a question and answer breakout session at 4:50 p.m. ET.